The following text field filters the results that follow as you type.
Why life science is booming in the UK and what that means for broker strategy.
Published on 27 February, 2026
The life science sector is booming in the UK. Yet many outside the sector might struggle to define what exactly a life science business is, often associated solely with pharmaceuticals or lab-based research.
In reality, this dynamic sector spans a wide range of businesses, many of which may already be sitting within brokers’ client books.
Here, we’ll provide some clarity on what life science really covers, why it matters, and how brokers can play a more strategic role in supporting clients in this fast-moving, high-growth space.
What do we mean by life science?
The life science umbrella goes far beyond traditional pharma and biotechnology. It also encompasses:
- Medical devices and diagnostics
- Digital health and AI-driven wellness tools
- Nutraceuticals: vitamins, supplements, functional foods
- Cosmetics and personal care products with medical claims
- Assistive technologies and rehabilitation equipment
In short, businesses that develop products or services aimed at improving health, wellbeing, or life quality may fall under the life science banner.
Why brokers should care
Life science is one of the UK’s most important growth engines.
The UK has built a series of thriving life science clusters, often anchored to world-class universities and NHS research hubs. Key hotspots include:
- Cambridge and the East of England – biotech and MedTech pioneers
- Oxford and the Golden Triangle – spinouts and IP-led businesses
- Manchester and the North West – digital health innovation
- Scotland (Edinburgh, Glasgow, Dundee) – diagnostics and health tech
According to the latest figures, the sector contributes around £100 billion to the economy, employing around 300,000 people*.
And the Government's Life science Sector Plan sets out a ten-year mission to harness British science and innovation to deliver long-term economic growth**.
As the country leans into its ambition to become a science and tech superpower, the momentum behind life science is only increasing.
From a broking perspective, this means three things:
- You may already have clients in scope, from medical start-ups to supplement manufacturers.
- Risks are often misclassified, and standard commercial policies rarely address the sector’s nuanced exposures.
- There’s a growing need for specialism – clients want brokers who understand their world and can support scale and compliance.
Five strategic themes shaping the sector in 2026
So, what are the key issues facing businesses in the sector?
Access to capital: Early-stage businesses need funding to survive the long development timelines common in life science. Venture capital is tightening, so businesses must demonstrate robust risk management and scalability to attract backing.
Regulatory scrutiny: With products that impact public health, regulatory frameworks are stringent. Businesses must navigate Medicines and Healthcare products Regulatory Agency approvals and global compliance hurdles – an area where risk advice can add huge value.
Talent shortages: Like many sectors, life science faces a talent crunch. Brokers should understand how staffing gaps affect operational resilience and business continuity.
Cyber and data exposure: Many life science businesses handle sensitive health data or run AI-driven platforms. Cyber risk is about breach response as well as reputational integrity and clinical safety.
Rise of hybrid health models: The line between wellness, MedTech, and consumer health is blurring. Think wearable diagnostics, remote monitoring tools, or personalised nutrition services. These present new regulatory grey areas and insurance complexities.
How brokers can respond
To support clients effectively, brokers need to:
- Spot the signals; Look beyond Standard Industrial Classification (SIC) codes. Ask questions about product development, clinical testing or medical claims.
- Reframe conversations; These are not "retail" or "tech" businesses. They require a lens that considers product liability, clinical trials, Intellectual Property protection and global distribution.
- Build networks; Align with insurers who understand the sector. Partner with law businesses, consultants, and compliance experts.
- Stay informed; Life science is fluid. Follow policy updates, innovation priorities, and trade developments.
The opportunity for brokers
By tuning into this sector, brokers can move up the value chain. Life science clients need cover alongside insight and guidance, from a partner who understands the pace and pressure of bringing health innovations to market.
Whether it’s an AI-powered rehab app, a wellness drink with health claims, or a MedTech business scaling internationally, these businesses are looking for brokers who speak their language.
Understanding life science isn’t just a nice-to-have. It’s a growth opportunity hiding in plain sight.
- Review your book for clients with health-related products or services.
- Upskill your team on life science risk factors and terminology.
- Identify insurer partners with credible life science propositions.
- Lead proactive conversations to reclassify risks where appropriate.
In a sector defined by innovation, your brokerage can become a critical part of the ecosystem – if you take the time to decode it.
Specialist protection for a specialist sector
As life science businesses evolve, insurance needs to evolve with them. A specialist life science proposition is designed to recognise the sector’s distinct risk profile, from product liability and IP to regulatory scrutiny and global distribution, giving brokers the confidence to place risks appropriately and support clients as they scale.
